These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Clinical consequences of polymorphic drug oxidation. Alván G Fundam Clin Pharmacol; 1991; 5(3):209-28. PubMed ID: 1937350 [TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of genetic polymorphisms of drug metabolism. Meyer UA; Zanger UM Annu Rev Pharmacol Toxicol; 1997; 37():269-96. PubMed ID: 9131254 [TBL] [Abstract][Full Text] [Related]
7. The genetic control of drug oxidation in the liver. Dayer P; Balant L; Fabre J Int J Clin Pharmacol Res; 1983; 3(6):421-5. PubMed ID: 6147316 [TBL] [Abstract][Full Text] [Related]
8. Genetic control of isoniazid metabolism in man. EVANS DA; MANLEY KA; McKUSICK VA Br Med J; 1960 Aug; 2(5197):485-91. PubMed ID: 13820968 [No Abstract] [Full Text] [Related]
9. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. Evans DA; Mahgoub A; Sloan TP; Idle JR; Smith RL J Med Genet; 1980 Apr; 17(2):102-5. PubMed ID: 7381862 [TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine. Bertilsson L; Dengler HJ; Eichelbaum M; Schulz HU Eur J Clin Pharmacol; 1980 Feb; 17(2):153-5. PubMed ID: 7371707 [TBL] [Abstract][Full Text] [Related]
11. Inheritance of phenytoin hypometabolism: a kinetic study of one family. Vasko MR; Bell RD; Daly DD; Pippenger CE Clin Pharmacol Ther; 1980 Jan; 27(1):96-103. PubMed ID: 7351122 [No Abstract] [Full Text] [Related]
12. Defective oxidation of drugs: pharmacokinetic and therapeutic implications. Eichelbaum M Clin Pharmacokinet; 1982; 7(1):1-22. PubMed ID: 7042170 [No Abstract] [Full Text] [Related]